Zobrazeno 1 - 10
of 46
pro vyhledávání: ''
Autor:
Thomas Pilgrim, Diego López-Otero, José Luis Zamorano, James Jin, Roxana Mehran, Cathy Chen, Peter Nordbeck, Eric Boersma, Envisage-Tavi Af Investigators, Holger Thiele, Christian Hengstenberg, Rainer Hambrecht, Fayaz A. Shawl, George Dangas, Nicolas M. Van Mieghem, Luis Nombela-Franco, Kentaro Hayashida, Piera Capranzano, Anil Duggal, Yusuke Watanabe, Pascal Vranckx, Josep Rodés-Cabau, Raul Moreno, Usman Baber, Roland Veltkamp, Petra Laeis, Marco Valgimigli, Hyo-Soo Kim, Felix Meincke, Richard A. Anderson, Patrick Ohlmann, Irene Lang, Hans Lanz, Masanori Yamamoto, Helge Möllmann, Shigeru Saito, Martin Unverdorben
Publikováno v:
New England Journal of Medicine, 385(23), 2150-2160. Massachussetts Medical Society
BACKGROUND The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. METHODS We conducted a multicenter, prospective
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Ken, Okumura, Masaharu, Akao, Tetsuro, Yoshida, Masahito, Kawata, Osamu, Okazaki, Shintaro, Akashi, Kenichi, Eshima, Kimihiko, Tanizawa, Masayuki, Fukuzawa, Takuya, Hayashi, Masahiro, Akishita, Gregory Y H, Lip, Takeshi, Yamashita
Publikováno v:
Okumura, K, Akao, M, Yoshida, T, Kawata, M, Okazaki, O, Akashi, S, Eshima, K, Tanizawa, K, Fukuzawa, M, Hayashi, T, Akishita, M, Lip, G Y H & Yamashita, T 2020, ' Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation ', New England Journal of Medicine, vol. 383, no. 18, pp. 1735-1745 . https://doi.org/10.1056/NEJMoa2012883
BACKGROUND: Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding. METHODS: We conducted a phase 3, multicenter,
Autor:
Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero
Publikováno v:
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075
BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path
Autor:
Toni Sarapohja, M. Luz, Iris Kuss, Aramis Investigators, Christian Kappeler, Matthew R. Smith, Amir Snapir, Boris Alekseev, Neal D. Shore, Teuvo L.J. Tammela, Mindaugas Jievaltas, Sergey Polyakov, Albertas Ulys, Karim Fizazi, Egils Vjaters
Publikováno v:
New England Journal of Medicine. 380:1235-1246
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resis
Autor:
Stephane OUDARD, David Olmos Hidalgo, María J. Ribal, Tomasz Drewa, ARANZAZU GONZALEZ-DEL-ALBA, Marcin Słojewski, Susan Ellard, Louis Lacombe, PABLO MAROTO REY, Javier Angulo, Adel Izmailov, Gwenaelle Gravis, Lisa Horvath, Boris Hadaschik, Ernesto Sanchez Sanchez, Florence Joly, Emmanuelle Bompas, Anders Kjellman, Hakim MAHAMMEDI, Arnauld VILLERS, Jose Luis Perez-Gracia, Carlos Ferrer Albiach
Publikováno v:
The New England Journal of Medicine, 378, 15, pp. 1408-1418
Poulsen, M H & SPARTAN Investigators 2018, ' Apalutamide treatment and metastasis-free survival in prostate cancer ', New England Journal of Medicine, vol. 378, no. 15, pp. 1408-1418 . https://doi.org/10.1056/NEJMoa1715546
The New England Journal of Medicine, 378, 1408-1418
Poulsen, M H & SPARTAN Investigators 2018, ' Apalutamide treatment and metastasis-free survival in prostate cancer ', New England Journal of Medicine, vol. 378, no. 15, pp. 1408-1418 . https://doi.org/10.1056/NEJMoa1715546
The New England Journal of Medicine, 378, 1408-1418
Contains fulltext : 193640.pdf (Publisher’s version ) (Open Access) BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in me
Autor:
David Westerman, Mary Ann Anderson, Mathias Bressel, Mark A. Dawson, Martin Dreyling, Sasanka M. Handunnetti, Juliana Di Iulio, Sarah-Jane Dawson, Rodney J. Hicks, Rishu Agarwal, Christiane Pott, Constantine S. Tam, Kate Burbury, Andrew W. Roberts, Stephen Lade, John F. Seymour, Gillian M. Turner
Publikováno v:
New England Journal of Medicine. 378:1211-1223
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy.
Autor:
Fizazi, Karim, Tran, Namphuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez Antolin, Alfredo, Alekseev, Boris Y., Ãzgã¼roglu, Mustafa, Dingwei, Ye, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary B., Chi, Korbenfeld E, Kim N., Metrebian, S, Kaen, L, Staneloni, E, Batagelj, E, Tan, H, Hovey, E, Woo, H, Frydenberg, M, Chua, W, D’Hondt, L, Evaraert, E, Verschaeve, V, Wynendaele, W, Schrijvers, D, Waltregny, D, Whenham, N, Demey, W, Franke, F, Panhoca, R, Damião, R, Zucca, L, Da Rosa, V, Reis, R, Scalabrini, A, Nahas, W, Girotto, G, Nogueira, A, Gomes, A, Coradazzi, A, Kurteva, G, Siemens, R, Gingerich, J, Fleshner, N, Fradet, Y, Morgan, S, North, S, Saad, F, Shayegan, B, Zalewski, P, Pinochet, R, Orellana, N, Ding, Q, Ye, Z, Xie, L, Du, C, Chen, Z, Huang, Y, Sun, Z, Li, H, Jin, J, Li, C, Wan, B, Tian, Y, Zhou, F, Xie, K, Yao, X, Qiu, M, Zou, Q, Na, Y, Sun, Y, Xue, B, Ma, L, Martinez, C, Salazar, M, Larios, C, Solano, S, Pavlik, I, Brodak, M, Hora, M, Büchler, T, Borre, M, Johansen, J, Mejlholm, I, Poulsen, M, Wittendorf, He, Tammela, T, Vaarala, M, Theodore, C, Staudacher, L, Villers, A, Laplaige, P, Suttman, H, Steuber, T, Natale, S, Jones, R, Tran, A, Mazhar, D, Mills, J, Nyirady, P, Salamon, C, Torzsok, F, Feher, J, Géczi, L, Lakatos, A, Keizman, D, Sella, A, Frank, S, Peer, A, Rosenbaum, E, Berger, R, Mermershtain, W, Carteni, G, Tonini, G, De Giorgi, U, Facchini, G, Berruti, Alfredo, Bracarda, S, Basso, U, Galli, L, Tortora, G, Alietta, M, Fukasawa, S, Suzuki, H, Hasumi, H, Tsuchiya, T, Uemura, H, Kanayama, H, Hashine, K, Sato, F, Matsumoto, H, Oya, M, Lee, Jl, Park, S, Keam, B, Yun, H, Kim, Y, Kang, B, Lee, K, Kim, C, Saad, M, Sundram, M, Calvo, D, Moreno, R, Rodriquez, J, Hernandez, C, van den Berg, H, De La Rosett, J, Van Moorse, R, Hunting, J, Hendriks, M, Kueppers, F, Gilling, P, Beaven, A, Holmes, M, Jassem, J, Oszukowska, E, Niezabitowski, J, Jaxa Larecka, D, Chwalinski, M, Swiniarski, P, Silva, C, Conceicãoa, P, Fraga, A, Mauricio, J, Rodrigues, T, Pinheiro, L, Lima, E, Palma Dos Reis, J, Volovat, C, Jinga, V, Harza, M, Alyasova, A, Budnik, N, Bychkov, Y, Izmaylov, A, Khvorosten, D, Matveev, V, Novsov, A, Vladimirov, V, Tevs, D, Sheveleva, L, Bulanov, A, Semenov, A, Fadeeva, N, Kulikov, E, Emelyanov, S, Karyakin, O, Shirinkin, V, Shkolnik, M, Lykov, A, Skopin, P, Kopyltsov, E, Mincik, I, Mir, O, Kliment, J, Mikurcik, E, Gajdos, M, Milichovsky, I, Malan, J, Bahlmann, J, Moshokoa, E, Madlala, T, Coetzee, L, Ribal, M, Miñana, B, Martinez Breijo, S, Carballido, J, Olmos, D, Requena, M, Morote, J, Damber, Je, Haggman, M, Nyman, C, Ljungberg, B, Bjartell, A, Ozen, H, Beduk, Y, Sozen, S, Cetinkaya, M, Ozyurt, M, Tansug, Z, Mungan, A, Tanidir, Y, Toktas, M, Hotko, E, Stus, V, Lyulko, O, Vinnyk, Y, Shparyk, Y, Sakalo, V, Bondarenko, I, Paramonov, V, Khareba, G, Hodos, V.
Publikováno v:
The New England journal of medicine, Vol. 377, no. 4, p. 352-360 (2017)
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivatio
Autor:
Hartmut Schmidt, Jeeyoung Oh, Yesim Parman, Teresa Coelho, Byoung Joon Kim, Akshay Vaishnaw, Ole B. Suhr, Chih-Chao Yang, Scott D. Solomon, Pushkal Garg, Sunita Goyal, Ivailo Tournev, Andrew Strahs, John L. Berk, Pritesh Gandhi, Shahram Attarian, Violaine Planté-Bordeneuve, Alejandra González-Duarte, Arnt V. Kristen, William O'Riordan, Kon Ping Lin, Mitsuharu Ueda, Philip N. Hawkins, Michelle M. Mezei, Jared Gollob, Jihong Chen, David Adams, Saraswathy V. Nochur, Thomas H. Brannagan, Peter J. Dyck, Josep M. Campistol, Giuseppe Vita, Marianne T. Sweetser, Michael Polydefkis, Yoshiki Sekijima, Juan Buades
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94e90139b6836f8b7a776e1f046b770
http://hdl.handle.net/2445/138257
http://hdl.handle.net/2445/138257
Autor:
Jean-Charles, Soria, Yuichiro, Ohe, Johan, Vansteenkiste, Thanyanan, Reungwetwattana, Busyamas, Chewaskulyong, Ki Hyeong, Lee, Arunee, Dechaphunkul, Fumio, Imamura, Naoyuki, Nogami, Takayasu, Kurata, Isamu, Okamoto, Caicun, Zhou, Byoung Chul, Cho, Ying, Cheng, Eun Kyung, Cho, Pei Jye, Voon, David, Planchard, Wu-Chou, Su, Jhanelle E, Gray, Siow-Ming, Lee, Rachel, Hodge, Marcelo, Marotti, Yuri, Rukazenkov, Suresh S, Ramalingam, Nhung, Nguyen
FLAURA ClinicalTrials.gov number, NCT02296125 BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::076a43b63fd193533f35e8f623070ac7
https://hdl.handle.net/10400.10/2348
https://hdl.handle.net/10400.10/2348